Blockbuster Anticlotting Drug Approved on Flawed Studies

What if the numbers that built its empire were never real? Quiet edits, missing records, and reversed outcomes now surface - exposing how your prescription might owe its power to paperwork, not proof.

STORY AT-A-GLANCE

• Ticagrelor, a blockbuster anticlotting drug, was approved despite FDA scientists warning it looked less safe and effective than older, cheaper alternatives like clopidogrel

• The landmark PLATO trial used to secure approval showed U.S. patients had worse outcomes on ticagrelor, yet those results were overridden by FDA leadership

• Investigations revealed serious problems with the trial, including altered death records, missing data, and inconsistent monitoring that favored ticagrelor

• Follow-up platelet studies were also misreported, with non-significant results published as significant and some listed authors denying participation

• Knowing these flaws allows you to ask about proven alternatives, reduce your personal heart risk through lifestyle, and avoid dependence on drugs pushed forward with weak, flawed evidence

Advertisement

Ticagrelor (Brilinta) has been promoted for years as a breakthrough in heart care, generating billions in sales and earning top placement in treatment guidelines across the world. It was positioned as a safer, more effective option than older blood thinners, and its reputation gave doctors reason to prescribe it widely.

The problem is that the foundation supporting this drug was never solid. From the beginning, questions about data reliability and trial integrity followed it. Instead of answers, patients and doctors were given a narrative of superiority that has not held up under closer inspection.

If you or someone close to you has been prescribed this drug, you should know its reputation as a leading treatment is built on shaky ground. When flaws in the science shape prescribing patterns, the risks fall squarely on the people taking the pills. That’s why it’s important to examine how this drug earned approval in the first place, what later investigations uncovered, and what safer paths forward look like for patients today.

FDA Scientists Warned Ticagrelor Was Less Safe Than Advertised

An in-depth investigation published in The BMJ revealed that the blockbuster anticlotting drug ticagrelor was approved over the strong objections of U.S. Food and Drug Administration (FDA) medical reviewers who warned the trial data was unreliable.¹ The approval hinged on the PLATO trial — the massive study that secured ticagrelor’s worldwide approval, which enrolled 18,624 patients across 43 countries.

While the published results claimed a reduction in cardiovascular deaths, heart attacks, and strokes, U.S. patients actually fared worse on ticagrelor compared to clopidogrel (Plavix). This raised serious questions about whether the benefits touted by ticagrelor’s maker AstraZeneca were real or manufactured.

• U.S. patients had worse outcomes — The FDA’s analysis revealed that patients in the U.S. had a 27% higher risk of major cardiovascular events when given ticagrelor, the exact opposite of what was seen in Europe and other regions. AstraZeneca argued that high aspirin doses in the U.S. explained this difference, but FDA scientists rejected that explanation as insufficient.

  This matters to you because if you were prescribed ticagrelor in the U.S., the very population where the drug performed poorly, your risk of harm could be higher than your doctor realizes.

• Lead FDA reviewer sounded the alarm — Dr. Thomas Marciniak, a medical officer at the FDA known for his rigorous reviews, concluded in a 47-page memo that ticagrelor appeared inferior in both safety and efficacy. He described AstraZeneca’s submission as “the worst in my experience regarding completeness of the submissions and the sponsor responding completely and accurately to requests.”

  His recommendation was to deny approval. Despite this, FDA leadership approved the drug. This means the green light came not from consensus among scientists but from administrative override.

• Data monitoring raised red flags — Another alarming detail from the investigation was that AstraZeneca monitored most trial sites themselves, except in four countries where independent organizations oversaw the process. In those four independently monitored countries — including the U.S. — ticagrelor performed worse than clopidogrel.

  Where the sponsor oversaw data collection, ticagrelor appeared superior. This inconsistency suggests that oversight and data handling directly shaped the reported outcomes, which should concern you if you trust that “gold standard” trials are always impartial.

• Death records were altered — The BMJ uncovered that adjudicators — those tasked with classifying patient outcomes — added 45 heart attacks to the clopidogrel group and zero to the ticagrelor group. Furthermore, among disputed deaths, the final classifications disproportionately favored ticagrelor.

  Even more troubling, The New England Journal of Medicine publication reported 905 deaths, while AstraZeneca’s internal records listed 983, leaving dozens unaccounted for.² If you rely on published medical journals to reflect reality, this discrepancy shows how data manipulation shaped the drug’s image.

• Mechanism of harm tied to bleeding and misclassified events — The trial design used a primary endpoint that combined death from vascular causes, heart attack, or stroke. This meant even small shifts in how events were classified could tip the scales.

  When deaths or heart attacks were reclassified in ticagrelor’s favor, the appearance of benefit emerged. For you, this demonstrates how outcome definitions — not just biology — determine whether a drug is labeled a “life saver” or a “risky bet.”

  What you take from this is not just about ticagrelor but about the system itself. If a multibillion-dollar drug could be approved over scientific objections, it shows how important it is for you to ask questions, look at alternatives, and demand transparency in how medical data is reported. Empowering yourself with this knowledge means you’re not blindly dependent on drugs that were fast-tracked through a flawed process.

Key Platelet Studies Were Riddled with Errors

The original BMJ investigation exposed major data integrity problems in the PLATO trial, casting doubt on whether the drug truly offered an advantage over cheaper rivals.³ Now, with generic versions set to hit the market, a follow-up investigation published in The BMJ has gone further by examining two smaller platelet studies that AstraZeneca used to defend ticagrelor’s effectiveness in acute coronary syndrome — ONSET/OFFSET and RESPOND.⁴

• Studies were inaccurately reported, casting serious doubt on AstraZeneca’s claims — These trials were central to convincing regulators and doctors that ticagrelor worked better, yet the primary endpoint results were misstated in Circulation, a leading cardiology journal.⁵ ⁶ This means the very foundation used to justify the drug’s “superiority” over cheaper options was built on flaws.

• Participants faced extreme and unusual demands — Patients in these platelet studies, who had stable coronary artery disease, were required to give large amounts of blood — up to 604 milliliters across visits, which is more than a full unit donated at a blood bank. Typically, platelet studies involve just one or two blood draws, but AstraZeneca’s required six within a single eight-hour period.

  As one trial investigator admitted, only the most committed participants could endure that burden. This unusual setup raises questions about whether the data reflected typical patients or only those willing to undergo intense procedures, which directly impacts whether the results apply to real life.

• Data gaps and missing records weakened credibility — The BMJ investigation found that more than 60 platelet readings were missing from the datasets submitted to the FDA. Even worse, some of the excluded results showed significantly higher platelet activity, suggesting ticagrelor did not inhibit clotting as strongly as advertised.

  Implausible readings, such as platelet activity increasing after treatment, were included in final analyses, but instead of being flagged, they were hidden through unpublished “data adjustments.” If you trusted those published results to reflect reality, the findings show that key data was either mishandled or left out.

• Authorship was misrepresented — Several individuals listed as study authors later denied involvement, while others who actively recruited patients were excluded. For example, Tonny Nielsen, identified as a Danish investigator and author, stated outright, “I did not participate in the RESPOND study.” Conversely, a Baltimore physician who enrolled 12 patients wasn’t credited.

Even the Study Methods Introduced Bias

Platelet aggregation, the lab test used to measure clotting, is notoriously sensitive to timing and technique. Experts told The BMJ that such tests are best done at a single site to ensure consistency, yet AstraZeneca spread them across 10 sites in multiple countries.⁷

The investigation could not confirm whether all staff received proper training, increasing the chance of inconsistent results. This matters for your safety because if platelet function was measured improperly, the claims about ticagrelor’s effectiveness lose validity.

• Statistical tricks distorted outcomes — RESPOND originally showed non-significant results, meaning ticagrelor did not reliably outperform clopidogrel. But by changing the definition of the primary endpoint, the published paper reported it as significant. That single shift turned ticagrelor into a “winner.” If you were ever told this drug had clear advantages, the truth is those advantages were manufactured by re-writing the rules of analysis.

• What this means for your health decisions — Victor Serebruany, a Johns Hopkins pharmacologist and one of ticagrelor’s earliest critics, summarized it bluntly: “If doctors had known what happened in these trials, they would never have started using ticagrelor.”⁸

  This means that the trust placed in ticagrelor’s science was misplaced, and drugs like clopidogrel were pushed aside based on faulty evidence. Armed with this knowledge, you can ask sharper questions about whether the medications you’re offered are backed by solid science — or by manipulated data.

How to Protect Yourself from Flawed Drug Approvals

The truth about ticagrelor’s approval process is unsettling. When a drug is pushed through despite serious doubts about safety and effectiveness, you’re left vulnerable. But you’re not powerless here. Your health depends on taking active steps to understand the risks, choose safer options, and avoid becoming dependent on treatments built on weak or manipulated science.

If you’ve been prescribed an anticlotting drug after a heart procedure, or if you’re caring for a loved one in that position, these steps give you a clear way to move forward.

1. Question the strength of the evidence — Before starting any drug, look into whether the key studies supporting it had problems with data accuracy, missing information, or conflicting results. In this case, ticagrelor’s studies were riddled with errors and misreporting. When you ask “What does the evidence actually show?” you set yourself up for better decisions.

2. Reduce your risk by addressing root causes — Anticlotting drugs are often prescribed because of lifestyle-driven heart disease. If you lower your risk through diet, movement, and reducing toxic exposures, you’ll rely less on drugs in the first place.

   Cut vegetable oils from your diet, avoid ultraprocessed foods, increase your intake of whole-food carbohydrates, and build strength through daily walking and regular resistance training. This improves your circulation and lowers clotting risk naturally.

3. Track your progress with the right markers — Instead of relying on outdated measures like total cholesterol, focus on health tests that actually reflect your metabolic health. Monitor your HOMA-IR score to track insulin resistance, check fasting glucose, and keep an eye on your triglyceride-to-HDL ratio.

   You can also use a simple blood pressure cuff at home to watch for improvements in circulation. Treat these numbers like checkpoints — every improvement is proof that your daily choices are moving you in the right direction and away from dependence on risky drugs.

4. Stay informed and proactive about drug safety — Don’t assume that just because a drug is FDA-approved, it’s the best choice. Ticagrelor proves that approvals often ignore serious flaws. Read investigations, follow updates from independent researchers, and ask yourself whether the benefits outweigh the risks. Knowledge puts you in charge, not the system.

By making these moves, you take back the control that was stripped away when flawed drugs were pushed into the system. Your health outcomes become less about pharmaceutical profits and more about what actually works for your body.

FAQs About the Anticlotting Drug Ticagrelor

Q: What is ticagrelor and why is it prescribed?

A: Ticagrelor, sold as Brilinta, is an anticlotting drug widely prescribed for patients with acute coronary syndrome, which includes heart attacks and unstable chest pain. It was marketed as superior to clopidogrel, an older and cheaper drug, based on clinical trial data that is now under serious scrutiny.

Q: Why are experts questioning the approval of ticagrelor?

A: The FDA’s own medical reviewers warned that ticagrelor performed worse than clopidogrel in U.S. patients and flagged major data quality issues in the landmark PLATO trial. Despite those warnings, FDA leadership approved the drug. Later investigations found missing data, altered death records, and inconsistencies that all favored ticagrelor.

Q: What new problems were uncovered in follow-up studies?

A: A 2025 BMJ investigation revealed that key platelet function studies used to support ticagrelor’s approval were misreported. Non-significant results were published as significant, more than 60 platelet test results were missing from FDA datasets, and some study authors denied involvement. These flaws raise serious doubts about whether ticagrelor truly offers benefits.

Q: How does this affect me if I’ve been prescribed ticagrelor?

A: If you’re on ticagrelor, you should know that its supposed advantages are not backed by consistent or reliable science. Patients in the U.S. — the very population where the drug was most heavily promoted — actually experienced worse outcomes, including higher risks of heart events.

Q: What steps can I take to protect myself?

A: You can reduce reliance on flawed drugs by asking about safer, proven alternatives, questioning the quality of evidence before starting new prescriptions, lowering your cardiovascular risk through diet and lifestyle, tracking your progress with simple health tools, and staying informed about drug safety investigations. These steps keep your health decisions in your hands instead of in the hands of pharmaceutical companies.

Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked.

The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. The subscription fee being requested is for access to the articles and information posted on this site, and is not being paid for any individual medical advice.

If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.

1. BMJ 2024;387:q2550

2. New England Journal of Medicine 2009 Sep 10;361(11):1045-57

3. BMJ 2024;387:q2550

4. BMJ 2025;389:r1201

5. Circulation Volume 120, Number 25

6. Circulation Volume 121, Number 10

7. BMJ 2025;389:r1201

8. BMJ 2025;389:r1201